全文获取类型
收费全文 | 333篇 |
免费 | 13篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 14篇 |
基础医学 | 34篇 |
口腔科学 | 18篇 |
临床医学 | 23篇 |
内科学 | 140篇 |
皮肤病学 | 4篇 |
神经病学 | 8篇 |
特种医学 | 38篇 |
外科学 | 17篇 |
综合类 | 3篇 |
预防医学 | 23篇 |
眼科学 | 1篇 |
药学 | 17篇 |
肿瘤学 | 13篇 |
出版年
2022年 | 3篇 |
2020年 | 2篇 |
2019年 | 3篇 |
2018年 | 4篇 |
2017年 | 6篇 |
2016年 | 4篇 |
2015年 | 4篇 |
2014年 | 14篇 |
2013年 | 12篇 |
2012年 | 14篇 |
2011年 | 12篇 |
2010年 | 11篇 |
2009年 | 6篇 |
2008年 | 17篇 |
2007年 | 12篇 |
2006年 | 9篇 |
2005年 | 15篇 |
2004年 | 7篇 |
2003年 | 6篇 |
2002年 | 2篇 |
2001年 | 3篇 |
2000年 | 3篇 |
1999年 | 6篇 |
1998年 | 12篇 |
1997年 | 13篇 |
1996年 | 19篇 |
1995年 | 13篇 |
1994年 | 14篇 |
1993年 | 15篇 |
1992年 | 3篇 |
1990年 | 2篇 |
1989年 | 8篇 |
1988年 | 9篇 |
1987年 | 10篇 |
1986年 | 9篇 |
1985年 | 9篇 |
1984年 | 5篇 |
1983年 | 4篇 |
1981年 | 4篇 |
1980年 | 6篇 |
1979年 | 2篇 |
1978年 | 3篇 |
1977年 | 4篇 |
1976年 | 3篇 |
1975年 | 2篇 |
1959年 | 2篇 |
1949年 | 1篇 |
1931年 | 1篇 |
1919年 | 1篇 |
1889年 | 1篇 |
排序方式: 共有354条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
Bensinger WI; Weaver CH; Appelbaum FR; Rowley S; Demirer T; Sanders J; Storb R; Buckner CD 《Blood》1995,85(6):1655-1658
Peripheral blood stem cells (PBSCs) are widely used in autologous transplantation because of ease of collection and rapid hematopoietic reconstitution. However, PBSCs have rarely been used for allogeneic transplantation because of concerns about donor toxicities from cytokine administration and the theoretical increased risk of graft- versus-host-disease (GVHD) from the large number of T cells infused. Eight patients with advanced malignancies received allogeneic PBSC transplants from genotypically HLA-identical sibling donors. All donors received 5 days of recombinant human granulocyte colony-stimulating factor (rhG-CSF; 16 micrograms/kg/day) subcutaneously and were leukapheresed for 2 days. After treatment of the patient with total body irradiation and cyclophosphamide (n = 7) or etoposide, thiotepa, and cyclophosphamide (n = 1), PBSCs were infused immediately after collection and without modification. All patients received cyclosporine and either methotrexate (n = 6) or prednisone (n = 2) for GVHD prophylaxis, rhG-CSF was well tolerated with mild bone pain requiring acetaminophen occurring in two donors. All patients engrafted and in seven hematopoietic recovery was rapid, with 500 neutrophils/microL achieved by day 18 and 20,000 platelets/microL by day 12. Complete donor engraftment was documented by Y chromosome analysis in all four sex-mismatched donor-recipient pairs tested and by DNA analysis in two sex-matched pairs. One patient died on day 18 of veno-occlusive disease of the liver with engraftment but before chromosome analysis could be performed (results are pending in 1 patient). A second patient died of fungal infection 78 days after transplant. Grade 2 acute GVHD occurred in two patients and grade 3 GVHD occurred in one patient. One patient is 301 days from transplant in remission with chronic GVHD; the remaining five patients are alive and disease free 67 to 112 days after transplantation. Preliminary results indicate that allogeneic PBSCs mobilized by rhG-CSF can provide rapid hematologic recovery without an appreciably greater incidence of acute GVHD than would be expected with marrow. Further follow-up is required to determine the incidence of chronic GVHD and any potential beneficial effects on relapse after transplant. 相似文献
5.
Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation 总被引:16,自引:10,他引:16
Bensinger WI; Clift R; Martin P; Appelbaum FR; Demirer T; Gooley T; Lilleby K; Rowley S; Sanders J; Storb R; Buckner CD 《Blood》1996,88(7):2794-2800
Allogeneic peripheral blood stem cell (PBSC) transplants from HLA- identical siblings were performed in 37 patients with advanced hematologic malignancies. Outcomes were compared to a historical group of 37 similar patients with advanced hematologic malignancies receiving bone marrow (BM) transplants from HLA-identical donors. The PBSC group and historical BM group were well matched for diagnosis, disease stage, age, and graft-versus-host disease (GVHD) prophylaxis. Patients received PBSC transplants between 1993 to 1995 while BM patients were treated between 1989 to 1994. Engraftment, measured by the time to reach a peripheral neutrophil count > 500/L and platelet count > 20,000/microL without transfusions, occurred on days 14 and 11 in the patients transplanted with PBSC compared to days 16 and 15 in the patients receiving BM (P = .00063, .00014). The PBSC group required a median of 8 U of red blood cells and 24 U of platelets compared to 17 U of red blood cells and 118 U of platelets for BM transplant recipients (P = .0005, .0001). The estimated risks of developing grades 2 to 4 acute GVHD were 37% for the PBSC group and 56% for the BM group (P = .18), while the estimated risks of grades 3 to 4 acute GVHD were 14% for the PBSC group and 33% for the BM group, P = .05). Chronic GVHD occurred in 7 of 18 evaluable patients receiving PBSC and 6 of 23 evaluable patients receiving BM, P = .5. The estimated risks of transplant-related mortality at 200 days were 27% versus 45% (P = .33) relapse were 70% versus 53% (P = .27) and of overall survival were 50% and 41% (P = .39) for patients transplanted with PBSC or BM, respectively. This retrospective comparison suggests that compared to marrow transplantation from HLA-identical donors, allogeneic PBSC transplantation from HLA-identical donors is associated with faster engraftment, fewer transfusions, and no greater incidence of acute or chronic GVHD. 相似文献
6.
Two patients with aplastic anemia were treated with high-dose cyclophosphamide and marrow transplantation from their normal, genetically identical twin. Both patients rapidly recovered normal marrow function, but marrow failure recurred 13 and 18 months later. Because donor and host pairs were identical twins, these cases of graft failure could not have resulted from the usual cause of graft failure, ie, immunological reactivity of host cells against unshared minor histocompatibility antigens of the donor. These results imply that there are at least two mechanisms responsible for graft failure after marrow transplantation for severe aplastic anemia. 相似文献
7.
Tatiana Forte Lopes Marcia Moreira Holcman Gerson Laurindo Barbosa Maria de Fatima Domingos Rosa Maria Oliveira Veiga Barreiros 《Revista do Instituto de Medicina Tropical de S?o Paulo》2014,56(5):369-374
Aedes aegypti is an important vector in Brazil being
the main vector of the dengue-fever. This paper employs survival curves to
describe the time in days from larvae to adult forms of Aedes
aegypti raised, individually and collectively, and compares it
during winter and spring when positioned inside and outside a laboratory. The
study was conducted in São Vicente, a coastal city in Southeastern Brazil.
The lowest water temperature in winter and in spring was 20 °C and the
highest was 26 °C in spring. Higher and more stable temperatures were
measured in the intra compared to the peri in both seasons. Consequently, larvae
positioned in the intra resulted in the lowest median time to develop in the
individual and collective experiment (nine and ten days,
respectively). At least 25% of the larvae positioned in the intra in
the individual experiment in the spring took only seven days to reach adulthood.
Sex ratios and the median time development by sex did not show significant
differences. These results indicate that efforts to control Aedes
aegypti must be continuous and directed mainly to prevent the
intra-domiciliary sites that can be infested in a week in order to reduce the
human-vector contact. 相似文献
8.
9.
Juliana Cruz da Silva Henrique Ataide Mariz Laurindo Ferreira da Rocha Júnior Priscilla Stela Santana de Oliveira Andrea Tavares Dantas Angela Luzia Branco Pinto Duarte Ivan da Rocha Pitta Suely Lins Galdino Maira Galdino da Rocha Pitta 《Clinics (S?o Paulo, Brazil)》2013,68(6):766-771
OBJECTIVES:
Hydroxychloroquine is an antimalarial agent that has been used in systemic lupus erythematosus and rheumatoid arthritis treatment for many years. Recently, novel mechanisms of action have been proposed, thereby broadening the therapeutic perspective of this medication. The purpose of this study was to evaluate the immunomodulatory activity of hydroxychloroquine in T helper 17 (Th17) cytokines in healthy individuals and patients.METHODS:
Eighteen female patients with systemic lupus erythematosus (mean age 39.0±12.9 years) and 13 female patients with rheumatoid arthritis (mean age 51.5±7.7 years) were recruited from Universidade Federal de Pernambuco-Brazil. The patients were included after fulfilling four classification criteria for systemic lupus erythematosus or rheumatoid arthritis from the American College of Rheumatology. After being stimulated with phorbol 12-myristate 13-acetate and ionomycin in the absence or presence of different concentrations of hydroxychloroquine, the interleukin 6, 17 and 22 levels were quantified with an enzyme-linked immunosorbent assay in culture supernatants of peripheral blood mononuclear cells from healthy individuals and patients.RESULTS:
We demonstrated that in peripheral blood mononuclear cells from healthy volunteers and in systemic lupus erythematosus and rheumatoid arthritis patients, there was a significant reduction in the IL-6, IL-17 and IL-22 supernatant levels after adding hydroxychloroquine.CONCLUSIONS
Our in vitro results demonstrated that hydroxychloroquine inhibits IL-6, IL-17 and IL-22 production and contributes to a better understanding of the mechanism of action of this medication. 相似文献10.
Weaver CH; Buckner CD; Longin K; Appelbaum FR; Rowley S; Lilleby K; Miser J; Storb R; Hansen JA; Bensinger W 《Blood》1993,82(7):1981-1984
Five syngeneic transplants were performed in four patients following myeloablative therapy using unmodified peripheral blood mononuclear cells (PBMCs) collected after the administration of recombinant human granulocyte colony stimulating factor (rhG-CSF) to normal donors. The only toxicity experienced by the four normal donors was bone pain. Four patients received two collections of PBMCs, and a second transplant was performed in one patient with one collection. The patients received a median of 20.53 x 10(8) total nucleated cells/kg (range 20 to 25.5), 11.3 x 10(8) total mononuclear cells/kg (range 6.52 to 17.2), 113.1 x 10(4)/kg CFU-GM (range 46.7 to 211.8) and 9.6 x 10(6) CD34+ cells/kg (range 1.6 to 12.6) Post-transplant growth factors were not administered. The median time to an absolute neutrophil count greater than 0.5 x 10(9)/L was 14 days (range 10 to 18). The median time to platelet transfusion independence was 11 days (range 10 to 13). Two patients had the number of CD3+ T lymphocytes determined in the pheresis product. An average of 3.04 x 10(10) CD3+ cells were collected per pheresis. This represents an approximate 1 log increase over the number of T lymphocytes in a typical bone marrow transplant. Rh-GCSF can be used to mobilize peripheral blood progenitor cells from normal donors with minimal toxicity. Studies of allogeneic transplants using PBMCs collected after rhG-CSF administration to determine permanent grafting ability and the incidence and severity of graft-versus-host disease are warranted. 相似文献